reports
- ING Helpdesk
Benelux Morning Notes
Ageas: The Saga continues. ASM International: KKR reportedly interested in ASM PT. D'Ieteren: Belron €8.1bn debt financing at better rates than expected. Elia: Challenges ahead, CEO appointment necessary. Gimv: €150-250m bond issue by Gimv controlling anchor investor WorxInvest. PostNL: Preparation letter on future of Dutch mail market sent to Parliament. Vonovia: Good progress on disposals
- Hilde Van Boxstael
- Michiel Declercq
- Wim Lewi
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List Update October 2024 – Adding NN Group
We maintain a defensive stance on the market for 2H24. The long anticipated expectations for interest rate cuts by central banks will finally come to pass. The election fever in the US is reaching boiling point and the conversations are becoming more polarised than before. Also corporate profit growth in Europe slows and the French elections have cast a negative spell. In Germany by-elections in the Eastern part showed a shift to extreme right and left that will make budget decisions even more ...
BEKB BEKAERT SA
ABN ABN AMRO BANK NV DEPOSITARY RECEIPTS
FAGR FAGRON SA
EVS EVS BROADCAST EQUIPMENT SA
XIOR XIOR STUDENT HOUSING N.V.
SOLB SOLVAY SA
COFB COFINIMMO SA
DIE D'IETEREN SA
SOF SOFINA SA
IBAB ION BEAM APPLICATIONS SA
ACKB ACKERMANS & VAN HAAREN NV
KIN KINEPOLIS GROUP NV
NN NN GROUP N.V.
TINC TINC COMM. VA
FUR FUGRO NV
SYENS SYENSQO
IBA and Jules Bordet Institute to lead IHI project Accelerate.EU to cr...
IBA and Jules Bordet Institute to lead IHI project Accelerate.EU to create complete Astatine-211 value chain A EUR 16 million Initiative to Establish Strategic EU Autonomy in Alpha Therapies for Cancer Louvain-la-Neuve, Belgium, October 3, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, is pleased to announce that the European Commission has approved the financing of the Accelerate.EU project launching on October 1, 2024. IBA’s key role in this new project...
IBA et l'Institut Jules Bordet piloteront le projet IHI Accelerate.EU ...
IBA et l'Institut Jules Bordet piloteront le projet IHI Accelerate.EU pour créer une chaîne de valeur complète pour l'Astate-211 Une initiative de 16 millions d'euros pour établir l'autonomie stratégique de l'UE en matière de thérapies alpha contre le cancer Louvain-la-Neuve, Belgique, 3 octobre 2024 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial de la technologie d’accélération de particules et le premier fournisseur mondial de solutions de production de radiopharmaceutiques, annonce aujourd’hui que la Commission européenne a approuvé le financement du projet Accelerate.E...
IBA - Regulated Information
IBA - Regulated Information (Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, October 1st, 2024 06:00 Summary of the notification IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on September 26, 2024. In its notification, Vallcara Limited indicate...
IBA SA – NOTIFICATION TRANSPARENCE
IBA SA – NOTIFICATION TRANSPARENCE (article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 1er octobre 2024, 18:00 Résumé de la notification IBA (Ion Beam Applications SA), le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, annonce devoir effectuer une notification en matière de transparence conformément à l'article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes (« loi transparence »), à la suite d’une notificati...
- Jacob Mekhael
Sequana Medical € 6m convertible and debt restructuring extend runway ...
Sequana reported 1H24 results and announced a new convertible loan of € 3.05m (additional tranche of € 3.05m), extending its runway into 1Q25. The company is exploring separating the DSR and alfapump businesses into Hive-Downs to solve for the lack of synergy between programs. Additionally, Sequana restructured its debt with Kreos, PMV, Belfius, and Sensinnovat. Responses to the FDA 90 Day letter will submitted on 1 October, and alfapump PMA approval continues to be expected by 1Q25.
- Jacob Mekhael
- Thomas Vranken
- Wim Hoste
- Jacob Mekhael
- Michiel Declercq
- Thomas Vranken
Life Sciences Conference 26.09.2024
This conference booklet is your guide to our Life Sciences Conference set to take place on Thursday, 26 September 2024 at our historic building at Grand Place in Brussels. This event offers the possibility to have one-on-one meetings and/or join pitch sessions with the following companies and their top management: Public: AUTOLUS | GALAPAGOS | HYLORIS | INVENTIVA | MAAT PHARMA | ONWARD MEDICAL | SEQUANA MEDICAL | UCB | ZEALAND PHARMA Private: CONFO TX | MRM HEALTH | PANTERA | SKYLINE DX
- ING Helpdesk
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Wim Lewi
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Wim Lewi
- Michiel Declercq
IBA Ready to Act (inium 225)
Earlier this week, IBA's joint venture PanTera secured € 93m in an oversubscribed Series A funding round, making it the largest in Belgian life science history. The post money valuation of € 280m implies a valuation of IBA's stake of € 88m or € 2.9ps, or comfortably above the previous book value of € 0.6ps. Incorporating this into our model, we increased our TP from € 16.0 to € 18.0 per share on Wednesday and reiterated our Buy rating. In this note, we take a closer look at the strong growth dri...
- ING Helpdesk
- Michiel Declercq
IBA Pantera gets € 280m valuation after largest Series A in Belgian LS...
This morning, IBA announced that Pantera secured € 93m in an oversubscribed series A round (the largest in Belgian life science history), valuing Pantera at € 280m post money valuation. Additionally, IBA and SFPIM will convert € 7.2m in convertible loans, while € 33.8m in debt has also been secured, bringing the total amount raised to € 134m. Following the transaction, IBA's will hold a 31.3% stake in Pantera, compared to 47.8% previously. The funds will be used primarily to support the construc...
- Guy Sips
- Michiel Declercq
- Sharad Kumar S.P
- Sharad Kumar S.P
Holdings Report - August 2024 KBCS Holdings Universe Up 0.5% Thanks To...
1M Performance - Absolute: During July'24 (1M period), the KBCS Holdings Universe posted a return of 0.5% which was mainly driven by multi-asset holdings (+1.7%) while single-asset holdings posted a negative return of -1.3%. The 3 top performers during the period were HAL Trust (+5.1%), Texaf (+2.9%), and The Infrastructure Company (TINC, +9.6%) while the 3 worst performers were Brederode (-2.8%), Solvac (-5.3%), and Whitestone Group (-7.2%). YTD Performance - Relative: On a YTD basis (as of A...
GBLB GROUPE BRUXELLES LAMBERT SA
HAL HAL TRUST
DIE D'IETEREN SA
SOF SOFINA SA
SOLV SOLVAC S.A.
GIMB GIMV NV
QFG QUEST FOR GROWTH
ACKB ACKERMANS & VAN HAAREN NV
TUB FINANCIERE DE TUBIZE S.A.
HEIO HEINEKEN HOLDING N.V.
KBCA KBC ANCORA SCA
TEXF TEXAF
BREB BREDERODE S.A.
TINC TINC COMM. VA
ROCK WHITESTONE GROUP
IBA’s joint venture PanTera secures EUR 93 million in oversubscribed S...
IBA’s joint venture PanTera secures EUR 93 million in oversubscribed Series A round to accelerate global actinium-225 production Louvain-la-Neuve, Belgium, September 11, 2024 – IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, is pleased to share the below press release from its joint venture PanTera, which is focussed on the production of actinium-225, a novel radioisotope used in a new class of targeted treatments for cancer. The Series A financing values PanTera at about EUR 280 million post money. Prior to the funding round, IBA had a 47.8% sharehold...
PanTera, la joint-venture d’IBA, obtient 93 millions d'euros lors d'un...
PanTera, la joint-venture d’IBA, obtient 93 millions d'euros lors d'une levée de fonds de série A sursouscrite pour accélérer la production mondiale d'actinium-225 Louvain-La-Neuve, Belgique, le 11 septembre 2024 - IBA (Ion Beam Applications S.A.), le leader mondial de la technologie d’accélération de particules, partage aujourd’hui le communiqué de presse ci-dessous concernant sa joint-venture PanTera qui a pour objectif d’assurer la production à grande échelle d'actinium-225, un radioisotope novateur utilisé dans une nouvelle classe de traitements ciblés contre le cancer. La levée de fon...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.